Copernicus Receives Issued U.S. Patent for Methods to Formulate Highly Efficient Non-Viral Gene Therapy Vectors.Business Editors/Health/Medical Writers CLEVELAND--(BUSINESS WIRE)--Jan. 17, 2003 Copernicus Therapeutics, Inc. announced that the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent Office has issued US patent 6,506,890 entitled "Method of Nucleic Acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. Compaction". Mark J. Cooper, M.D., Senior Vice President of Science and Medical Affairs said, "This highly reproducible method of formulating non-viral expression vectors results in stable compacted DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. nanoparticles that can be concentrated and stored for long periods of time. These non-viral DNA nanoparticles are able to transfect even non-dividing cells at high efficiency. Our recently completed Phase I/II clinical trial involving subjects with cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. utilized DNA nanoparticles that were manufactured at Copernicus using this formulation method." "Copernicus has established a very broad and enabling position in the field of gene therapy," said Robert C. Moen, M.D., Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Copernicus. "Our intellectual property positions us uniquely in this field. Given the dangers inherent with viral vectors, our technology permits robust gene transfer into cells in animals or humans without induction of inflammation or immunologic toxicities. This patent covers a well-controlled and efficient method of formulating compacted DNA that can be readily scaled-up for manufacturing large quantities of DNA nanoparticles. This formulation of DNA nanoparticles is commercially relevant and central to our development of novel therapeutics. We expect to broadly partner this effective gene transfer platform with other pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. ." Copernicus Therapeutics, Inc. is advancing novel targeting and delivery systems with broad applications in human therapeutics and vaccines. Copernicus' technologies include a multi-component delivery platform that can be applied to nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. to develop therapies for a variety of human diseases and a targeting platform enabling the efficient uptake of drugs by specific cells and tissues. The Company's targeting and delivery platforms are complementary and can be combined to enhance the efficacy and safety of existing drugs or to create novel therapeutics. The Company's initial therapeutic product is being developed for the cystic fibrosis market and the Company recently completed a Phase I/II clinical trial for this indication. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion